MCA Scientific Events – 4th Congress on Congenital Cytomegalovirus (cCMV) 2025 (Videos)

Comprehensive Updates in Congenital Cytomegalovirus, Maternal-Fetal Infection, Prenatal Diagnosis, Neonatal Care, Antiviral Therapy, and Vaccine Development

Stay at the forefront of congenital infection management with the MCA Scientific Events – 4th Congress on Congenital Cytomegalovirus (cCMV) 2025, an advanced international continuing medical education (CME) program dedicated to the prevention, diagnosis, treatment, and long-term management of congenital cytomegalovirus (cCMV). Bringing together world-renowned experts in maternal-fetal medicine, neonatology, pediatric infectious diseases, virology, and immunology, this comprehensive congress provides the latest scientific evidence and practical clinical guidance covering the entire spectrum of congenital CMV—from pregnancy through infancy.

Held November 20–21, 2025, in Naples, Italy, with both in-person and online participation, the congress is led by internationally recognized experts Prof. Yves Ville (France), Prof. Efraim Bilavsky (Israel), and Prof. Francesco Raimondi (Italy). Through expert lectures, multidisciplinary discussions, clinical case reviews, and evidence-based presentations, participants gain practical insight into maternal screening, prenatal diagnosis, fetal imaging, antiviral therapies, neonatal management, hearing preservation, neurological outcomes, and future vaccine development.

Designed for clinicians and researchers involved in maternal, fetal, and pediatric healthcare, this program emphasizes multidisciplinary collaboration and precision medicine approaches to improve outcomes for infants affected by congenital CMV.

Product Details

• Course: 4th Congress on Congenital Cytomegalovirus (cCMV) 2025
• Provider: MCA Scientific Events
• Conference Dates: November 20–21, 2025
• Location: Naples, Italy (Hybrid: In-Person & Online)
• Format: Videos
• Language: English
• Educational Level: Advanced

Course Overview

Congenital cytomegalovirus remains the most common congenital viral infection worldwide and is a leading cause of sensorineural hearing loss, neurodevelopmental impairment, and long-term childhood disability. Advances in prenatal diagnosis, fetal imaging, molecular diagnostics, antiviral therapy, and neonatal screening continue to reshape clinical management and improve patient outcomes.

The 4th Congress on Congenital Cytomegalovirus 2025 provides a comprehensive review of current evidence and emerging innovations in cCMV care. International faculty discuss maternal screening strategies, serologic testing, fetal assessment, non-invasive prenatal testing, digital PCR, ultrasound, fetal MRI, antiviral therapy during pregnancy, neonatal treatment, hearing preservation, neurodevelopmental outcomes, and ongoing vaccine research.

Participants gain practical, evidence-based knowledge that can be directly applied to maternal-fetal medicine, neonatal care, pediatric infectious disease practice, and multidisciplinary congenital infection programs.

What You’ll Learn

After completing this course, participants will be able to:

• Apply current international recommendations for CMV screening during pregnancy.
• Interpret maternal serologic testing for primary and non-primary CMV infection.
• Utilize prenatal diagnostic tools, including invasive testing and digital PCR.
• Integrate ultrasound and fetal MRI findings into prenatal CMV assessment.
• Optimize antiviral treatment strategies during pregnancy and infancy.
• Recognize the long-term neurological and auditory complications of congenital CMV.
• Evaluate hearing loss progression and treatment options in affected children.
• Understand current research on CMV vaccine development and future preventive strategies.

Comprehensive Topics Covered

Congenital Cytomegalovirus (cCMV)

Review the epidemiology, virology, transmission, and clinical impact of congenital CMV infection across pregnancy, fetal life, and early childhood.

Topics include:

• Congenital CMV infection
• Maternal infection
• Vertical transmission
• Fetal infection
• Neonatal CMV
• Clinical manifestations
• Long-term follow-up

Maternal Screening & Diagnosis

Develop a practical understanding of screening strategies and laboratory evaluation for CMV during pregnancy.

Topics include:

• Maternal screening
• Serologic testing
• Primary infection
• Non-primary infection
• IgG avidity testing
• Risk assessment
• International screening practices

Faculty review the advantages and limitations of current screening approaches across different healthcare systems.

Prenatal Diagnosis

Learn modern diagnostic techniques for confirming fetal CMV infection.

Topics include:

• Non-invasive prenatal testing (NIPT)
• Amniocentesis
• Digital PCR
• Molecular diagnostics
• Prenatal laboratory testing
• Diagnostic algorithms

Participants gain practical guidance on selecting appropriate diagnostic strategies based on gestational age and clinical presentation.

Fetal Imaging

Strengthen your ability to identify congenital CMV manifestations using advanced prenatal imaging.

Topics include:

• Obstetric ultrasound
• Fetal MRI
• Brain abnormalities
• Growth assessment
• Structural anomalies
• Prognostic imaging

Faculty discuss imaging findings that influence prognosis and prenatal counseling.

Antiviral Therapy

Review current evidence regarding antiviral treatment before and after birth.

Topics include:

• Antiviral medications
• Pregnancy treatment
• Neonatal antiviral therapy
• Treatment indications
• Drug safety
• Clinical outcomes

Neonatal & Pediatric Management

Explore multidisciplinary approaches to caring for infants with congenital CMV.

Topics include:

• Neonatal assessment
• Pediatric follow-up
• Developmental surveillance
• Multidisciplinary care
• Long-term monitoring

Hearing Loss & Neurodevelopment

Understand the major long-term complications associated with congenital CMV.

Topics include:

• Sensorineural hearing loss
• Audiologic monitoring
• Inner ear development
• Neurological disorders
• Developmental delay
• Autism spectrum research

Faculty discuss early detection, intervention, and long-term outcome optimization.

Immunology & Vaccine Development

Review the latest scientific advances in CMV immunology and vaccine research.

Topics include:

• Immune response
• Vaccine development
• Prevention strategies
• Future therapies
• Translational research

Participants gain insight into one of the most promising areas of congenital infection prevention.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

• Evaluate maternal CMV screening strategies used internationally.
• Interpret serologic testing for primary and non-primary CMV infection.
• Apply prenatal diagnostic tools, including invasive testing and digital PCR.
• Integrate ultrasound and MRI findings into fetal prognosis.
• Assess antiviral treatment options during pregnancy and infancy.
• Recognize neurological and auditory complications associated with congenital CMV.
• Monitor hearing loss progression and evaluate therapeutic interventions.
• Discuss advances in CMV vaccine development and future preventive strategies.

Educational Highlights

• Congenital Cytomegalovirus (cCMV)
• Maternal-Fetal Medicine
• Prenatal Diagnosis
• Maternal Infection
• Vertical Transmission
• Neonatal Medicine
• Pediatric Infectious Diseases
• Obstetric Ultrasound
• Fetal MRI
• Digital PCR
• Serologic Testing
• Antiviral Therapy
• Sensorineural Hearing Loss
• Audiology
• Neurodevelopment
• Autism Spectrum Research
• Virology
• Vaccine Development
• Precision Medicine
• Continuing Medical Education (CME)

Why This Course Stands Out

The MCA Scientific Events – 4th Congress on Congenital Cytomegalovirus 2025 offers one of the most comprehensive educational programs dedicated exclusively to congenital CMV. Covering every stage from pregnancy through infancy, the congress combines cutting-edge research, international clinical guidelines, advanced prenatal diagnostics, fetal imaging, antiviral therapy, audiologic outcomes, and vaccine development into a practical, multidisciplinary curriculum. Its global faculty and evidence-based approach make it an invaluable resource for clinicians seeking to improve maternal, fetal, and neonatal outcomes in congenital CMV infection.

Target Audience

This educational activity is ideal for:

• Obstetricians
• Gynecologists
• Maternal-Fetal Medicine Specialists
• Pediatricians
• Neonatologists
• Infectious Disease Specialists
• Pediatric Infectious Disease Physicians
• Virologists
• Audiologists
• Immunologists
• Fetal Medicine Specialists
• Obstetrics & Gynecology Residents
• Neonatal Fellows
• Pediatric Fellows
• Healthcare Professionals involved in maternal, fetal, and neonatal care

Why Choose This Course?

Whether you specialize in maternal-fetal medicine, neonatology, pediatrics, infectious diseases, or fetal imaging, the MCA Scientific Events – 4th Congress on Congenital Cytomegalovirus 2025 delivers an outstanding evidence-based review of congenital CMV. Featuring internationally recognized experts, multidisciplinary discussions, practical diagnostic strategies, advanced prenatal imaging, antiviral treatment updates, and emerging vaccine research, this program equips clinicians with the knowledge needed to optimize care from pregnancy through infancy.

Topics

Thursday, 20 November 2025

• 09:00 – 09:10 | WELCOME FROM CONGRESS PRESIDENTS: Yves Ville (France), Francesco Raimondi (Italy), Efraim Bilavsky (Israel)

• 09:10 – 10:40 | SESSION 1 – SCREENING IN PREGNANCY (Chairs: Yves Ville, France; Tiziana Lazzaroto, Italy)

  • 09:10 – 09:40 | Screening in pregnancy, in Italy and in France

    • Oral Communication: Outcome of primary CMV infection in pregnancy in Italy: data from a large multicentric cohort before and after the introduction of valacyclovir in the clinical practice at country level (Lorenzo Zammarchi, Italy)

    • Oral Communication: Congenital Cytomegalovirus Infection in Children Born to Mothers with Primary CMV Infection Treated with Valaciclovir: Analysis of the Multi-center MEGAL-ITALI Study (Elisabetta Venturini, Italy)

    • Oral Communication: Implementation of a national system for reporting and monitoring primary maternal CMV infections in France, in response to the HAS recommendations (Sophie Alain, France)

  • 09:40 – 10:00 | Serology made simple, or nearly (Marianne Leruez Ville, France)

  • 10:00 – 10:20 | How can we help pre-immune women? (Daniele Lilleri, Italy)

  • 10:20 – 10:40 | Discussion

• 10:40 – 11:20 | SESSION 2 – Oral communications (Chairs: Anna Gonce, Spain; Christelle Vauloup-Fellous, France)

  • Oral Communication: Occurrence of situations in which early CMV screening serology (<14 weeks of gestation) poses interpretative challenges (Christelle Vauloup-Fellous, France)

  • Oral Communication: CMV-Scan: a highly sensitive serological assay to detect maternal CMV non-primary infection (Ariane Larouche, Canada)

  • Oral Communication: Reduction of voluntary termination of pregnancy in pregnant women with primary Cytomegalovirus infections treated with valaciclovir (Alice Bonetti, Italy)

  • Oral Communication: Evolving Trends in Maternal Screening and First-Trimester Treatment: Data from the French National Herpesvirus Reference Center (Elodie Ribot, France)

  • Oral Communication: Beyond the Tip of the Iceberg: The Clinical Impact of Maternal Non-Primary CMV Infection ICCG- Israel Congenital CMV Group (Goni Peleg, Israel)

• 11:30 – 12:00 | COFFEE BREAK

• 12:00 – 14:10 | SESSION 3 – PRENATAL DIAGNOSIS (Chairs: Valentine Faure-Bardon, France; Marie-Luce Delforge, Belgium)

  • NIPT for CMV in pregnancy (Brigitte Faas, The Netherlands)

  • Invasive prenatal diagnosis (Nicolas Bourgon, France)

  • Is there more for serology to say? (Alfred Bissinger, Germany (online))

  • Secondary prevention, an international registry (Christros Chatzakis, United Kingdom)

  • 13:20 – 13:40 | Discussion

• 13:40 – 14:30 | LUNCH / POSTER VIEWING

• 14:30 – 15:20 | SESSION 4 – Oral Communications (Chairs: Jacques Fourgeaud, France; Caroline De Coninck, Belgium)

  • Beyond Real-Time PCR: diagnostic accuracy of Digital PCR in the Pre-natal Diagnosis of Congenital CMV Infection (Liliana Gabrielli, Italy)

  • High-Dose Valacyclovir in Primary Cytomegalovirus Infection During Pregnancy: Effects on Immune Modulation and Maternal Serologic Response (Silvio Tartaglia, Italy)

  • Successful prevention of fetal CMV infection by valacyclovir and the interval between maternal infection and treatment initiation, a retrospective study (Jacob Amir, Israel)

  • Evaluation of MyCMV: A Tool to Enhance the Diagnosis of Cytomegalovirus Infection During Pregnancy (Jacques Fourgeaud, France)

  • Discussion

• 15:20 – 15:50 | COFFEE BREAK

• 15:50 – 17:20 | SESSION 5 – PROGNOSIS OF FETAL INFECTION (Chairs: Olivier Picone, France; Francesco Raimondi, Italy)

  • How to combine ultrasound and MRI? (Yves Ville, France)

  • Biology of an infected fetus for best and for worse (Anna Gonce, Spain)

  • Pharmacology of antiviral drugs in pregnancy (Valentine Faure-Bardon, France)

  • 16:50 – 17:20 | Discussion

• 17:20 – 18:10 | SESSION 6 – Oral communications (Chairs: Alfred Bissinger, Germany (online); Hermione Lyall, United Kingdom)

  • Inhibitory effect of antivirals on CMV infection in human stem cell-derived neural systems (Renata Vieira De Sa, The Netherlands)

  • Rate of post-amniocentesis transmission in pregnant women with primary cytomegalovirus infection treated with valaciclovir (Piera d’Angelo, Italy)

  • Congenital cytomegalovirus causes increased expression of neutrophil granule genes and suppression of innate immune response genes (Helen Payne, United Kingdom)

  • 18:00 – 18:10 | (Reserved block, unspecified details)

Friday, 21 November 2025

• 09:00 – 11:00 | SESSION 7 – The present and future of children with congenital CMV (Chairs: Ann Vossen, Belgium; Jacob Amir, Israel)

  • Impact of CMV on the Inner Ear – Looking through the Developmental Lens (Sharon Cushing, Canada)

  • Redefining the “Asymptomatic” Child in the Emerging Era of Universal cCMV Screening (Mark Schleiss, United States)

  • The link between cCMV and the autistic spectrum? (Marianne Leruez Ville & David Grévent, France)

  • How Close Are We? Prospects and Predicaments in Realizing the Goal of Licensing a Vaccine for Prevention of Congenital CMV (Mark Schleiss, United States)

  • Oral Communication: Beyond Hearing and Vision: Pilot Data on Olfactory Function in Congenital Cytomegalovirus (Serena Salomè, Italy)

  • Oral Communication: cCMV infection and risk of autism spectrum and other neurodevelopmental disorders in a large patient population in Northern California (Tara Greenhow, United States)

  • Oral Communication: Educational attainment, absenteeism, and special educational needs outcomes in school children up to age 10/11 with congenital cytomegalovirus (cCMV): A population-based cohort study using linked education and hospital data from England (Ayana Cant, United Kingdom)

  • 11:00 – 11:30 | Discussion

• 11:30 – 12:20 | COFFEE BREAK & POSTER WALK

• 12:20 – 13:30 | SESSION 8 – Hearing loss on children with congenial CMV (Chairs: Anna Rita Fetoni, Italy; Efraim Bilavsky, Israel)

  • Characteristics of Progression in Hearing Loss in Children with cCMV (Sharon Cushing, Canada)

  • An Enzymatic Assay for Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus (Willow Chernoske, United States)

  • CMV-specific IFN-γ responses post QuantiFERON CMV test at birth correlate with symptoms at birth and long-term outcome in infants with congenital cytomegalovirus infection (Vana Papaevangelo, Greece)

  • 13:00 – 13:30 | Discussion

• 13:30 – 14:30 | LUNCH AND POSTER VIEWING

• 14:30 – 15:00 | Debate on Antiviral treatment in children with late onset hearing loss

  • PRO – Efraim Bilavsky, Israel

  • CONS – Ann Vossen, Belgium

• 15:00 – 15:15 | Discussion

• 15:15 – 15:30 | CLOSING REMARKS: Yves Ville (France), Francesco Raimondi (Italy), Efraim Bilavsky (Israel)